Uncategorized
Analysis: Lucentis may be more cost-effective than Eylea for DME
VIENNA — A cost-effectiveness analysis based on Protocol T results found considerably higher costs and minimal gain in quality-adjusted life-years with Eylea compared with Lucentis for the treatment of diabetic macular edema, leading to the conclusion that Lucentis may be more cost-effective.“We used the Markov model, which takes visual acuity and divides it into groups from best to worst vision, and then we used an algorithm to sort these visual acuities into visual impairment costs and QALYs,” Nancy Holekamp, MD, said at the American Society of Retina Specialists meeting.